Advanced search
2 files | 1.66 MB

Selective glucocorticoid receptor modulation : new directions with non-steroidal scaffolds

Nora Sundahl (UGent) , Jolien Bridelance (UGent) , Claude Libert (UGent) , Karolien De Bosscher (UGent) and Ilse Beck (UGent)
Author
Organization
Abstract
Glucocorticoids remain the frontline treatment for inflammatory disorders, yet represent a double-edged sword with beneficial therapeutic actions alongside adverse effects, mainly in metabolic regulation. Considerable efforts were made to improve this balance by attempting to amplify therapeutic beneficial anti-inflammatory actions and to minimize adverse metabolic actions. Most attention has focused on the development of novel compounds favoring the transrepressing actions of the glucocorticoid receptor, assumed to be important for anti-inflammatory actions, over the transactivating actions, assumed to underpin the undesirable actions. These compounds are classified as selective glucocorticoid receptor agonists (SEGRAs) or selective glucocorticoid receptor modulators (SEGRMs). The-latter-class is able to-modulate-the activity of a GR agonist and/or may not classically bind the glucocorticoid receptor ligand-binding pocket. SEGRAs and SEGRMs are collectively denominated SEGRAMs (selective glucocorticoid receptor agonists and modulators). Although this transrepression vs transactivation concept proved to be too simplistic, the developed SEGRAMs were helpful in elucidating various molecular actions of the glucocorticoid receptor, but have also raised many novel questions. We discuss lessons learned from recent mechanistic studies of selective glucocorticoid receptor modulators. This is approached by analyzing recent experimental insights in comparison with knowledge obtained using mutant GR research, thus clarifying the current view on the SEGRAM field. These insights also contribute to our understanding of the processes controlling glucocorticoid-mediated side effects as well as glucocorticoid resistance. Our perspective on non-steroidal SEGRAs and SEGRMs considers remaining opportunities to address research gaps in order to harness the potential for more safe and effective glucocorticoid receptor therapies.
Keywords
Glucocorticoid receptor, Glucocorticoids, Selective glucocorticoid receptor modulator, Compound A, Side effects, Glucocorticoid resistance, FACTOR-KAPPA-B, COLLAGEN-INDUCED ARTHRITIS, SKELETAL-MUSCLE ATROPHY, HUMAN OCULAR CELLS, GENE-EXPRESSION, ANTIINFLAMMATORY PROPERTIES, TRANSCRIPTIONAL ACTIVITY, SYNOVIAL FIBROBLASTS, RHEUMATOID-ARTHRITIS, RESPONSE ELEMENTS

Downloads

  • 632a-Sundahl et al. Suppl. tabel.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 142.45 KB
  • 632-Sundahl et al..pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.52 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Sundahl, Nora, Jolien Bridelance, Claude Libert, Karolien De Bosscher, and Ilse Beck. 2015. “Selective Glucocorticoid Receptor Modulation : New Directions with Non-steroidal Scaffolds.” Pharmacology & Therapeutics 152: 28–41.
APA
Sundahl, N., Bridelance, J., Libert, C., De Bosscher, K., & Beck, I. (2015). Selective glucocorticoid receptor modulation : new directions with non-steroidal scaffolds. PHARMACOLOGY & THERAPEUTICS, 152, 28–41.
Vancouver
1.
Sundahl N, Bridelance J, Libert C, De Bosscher K, Beck I. Selective glucocorticoid receptor modulation : new directions with non-steroidal scaffolds. PHARMACOLOGY & THERAPEUTICS. 2015;152:28–41.
MLA
Sundahl, Nora, Jolien Bridelance, Claude Libert, et al. “Selective Glucocorticoid Receptor Modulation : New Directions with Non-steroidal Scaffolds.” PHARMACOLOGY & THERAPEUTICS 152 (2015): 28–41. Print.
@article{6896362,
  abstract     = {Glucocorticoids remain the frontline treatment for inflammatory disorders, yet represent a double-edged sword with beneficial therapeutic actions alongside adverse effects, mainly in metabolic regulation. Considerable efforts were made to improve this balance by attempting to amplify therapeutic beneficial anti-inflammatory actions and to minimize adverse metabolic actions. Most attention has focused on the development of novel compounds favoring the transrepressing actions of the glucocorticoid receptor, assumed to be important for anti-inflammatory actions, over the transactivating actions, assumed to underpin the undesirable actions. These compounds are classified as selective glucocorticoid receptor agonists (SEGRAs) or selective glucocorticoid receptor modulators (SEGRMs). The-latter-class is able to-modulate-the activity of a GR agonist and/or may not classically bind the glucocorticoid receptor ligand-binding pocket. SEGRAs and SEGRMs are collectively denominated SEGRAMs (selective glucocorticoid receptor agonists and modulators). Although this transrepression vs transactivation concept proved to be too simplistic, the developed SEGRAMs were helpful in elucidating various molecular actions of the glucocorticoid receptor, but have also raised many novel questions. We discuss lessons learned from recent mechanistic studies of selective glucocorticoid receptor modulators. This is approached by analyzing recent experimental insights in comparison with knowledge obtained using mutant GR research, thus clarifying the current view on the SEGRAM field. These insights also contribute to our understanding of the processes controlling glucocorticoid-mediated side effects as well as glucocorticoid resistance. Our perspective on non-steroidal SEGRAs and SEGRMs considers remaining opportunities to address research gaps in order to harness the potential for more safe and effective glucocorticoid receptor therapies.},
  author       = {Sundahl, Nora and Bridelance, Jolien and Libert, Claude and De Bosscher, Karolien and Beck, Ilse},
  issn         = {0163-7258},
  journal      = {PHARMACOLOGY \& THERAPEUTICS},
  language     = {eng},
  pages        = {28--41},
  title        = {Selective glucocorticoid receptor modulation : new directions with non-steroidal scaffolds},
  url          = {http://dx.doi.org/10.1016/j.pharmthera.2015.05.001},
  volume       = {152},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: